SCHEMBL22265490

SCHEMBL22265490

CCCCCCCCNc1ccc(C(N)=NO)cn1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 5/20 0.63
GAA P10253 2/20 0.51
RAB9A P51151 2/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.51
MAPT P10636 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
HDAC1 Q13547 7/20 0.50
HDAC2 Q92769 7/20 0.50
EPHX2 P34913 1/20 0.45
CNR2 P34972 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
DNM2 P50570 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22265488 1.00 HCAR3 (0.63) HCAR3GAARAB9ANPC1LMNA
SCHEMBL3807127 0.85 HCAR3 (0.47) HCAR3GAARAB9AEPHX2ADRA2A
SCHEMBL3807125 0.85 HCAR3 (0.47) HCAR3GAARAB9AEPHX2ADRA2A
SCHEMBL1680894 0.82 HCAR3 (0.76) HCAR3EPHX2CNR2
SCHEMBL1728772 0.81 HCAR3 (0.44) HCAR3GAARAB9AADRA2AADRA2B
SCHEMBL1728771 0.81 HCAR3 (0.44) HCAR3GAARAB9AADRA2AADRA2B
SCHEMBL11246840 0.79 HCAR3 (0.97) HCAR3TP53EPHX2
Hydrochloric Acid SCHEMBL11180843 0.78 HCAR3 (0.94) HCAR3TP53EPHX2
SCHEMBL22265387 0.78 SPHK1 (0.47) GAARAB9ANPC1LMNATP53
SCHEMBL22265385 0.78 SPHK1 (0.47) GAARAB9ANPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
EP-3914592-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2021-12-01 EP disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 HCAR3 4414/4885GAA 3521/4885RAB9A 4302/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 HCAR3 4183/4885GAA 4800/4885RAB9A 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.